South Korea Patient Derived Xenografts/PDX Models Market (2025-2030)
The South Korea Patient Derived Xenografts/PDX Models Market was valued at $4 Million in 2025 and projected to reach to $6.4 Million by 2030, representing a compound annual growth rate of 9.8%. South Korea's PDX models market is positioned for steady growth as the country strengthens its position in precision oncology research.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea Patient Derived Xenografts/PDX Models Market Trends and Insights
- South Korea's advanced biotechnology infrastructure and strong investment in personalized medicine are positioning the country as a key player in preclinical oncology research.
- The market in South Korea is driven by increasing adoption of PDX models among pharmaceutical companies and research institutions seeking more accurate tumor biology representation compared to traditional cell lines. South Korea's pharmaceutical sector is increasingly leveraging PDX technology to accelerate drug development timelines and improve clinical trial success rates.
- Between 2025 and 2030, South Korea is expected to see heightened demand from contract research organizations (CROs) and academic medical centers focusing on precision oncology.
- South Korea's regulatory environment and government support for life sciences innovation are creating favorable conditions for market expansion, with the 9.8% CAGR reflecting sustained investment in translational cancer research and biomarker-driven therapeutic development..
Key Market Statistics
- CAGR (2025-2030) 9.8% CAGR
- Market Size, 2025 ~USD 4 Million
- Forecast, 2030 ~USD 6.4 Million
- Country South Korea
South Korea Patient Derived Xenografts/PDX Models Market Overview
Market Valuation Growth :
South Korea's PDX models market is valued at $4.0 million in 2025, with projections reaching $6.4 million by 2030, representing a robust 9.8% CAGR over the forecast period.
Advanced Biotech Infrastructure :
South Korea's state-of-the-art biotechnology facilities and research institutions provide a strong foundation for PDX model development and preclinical oncology research applications.
Personalized Medicine Investment :
Significant government and private sector investment in personalized medicine initiatives is accelerating adoption of PDX models for tailored cancer treatment development in South Korea.
Preclinical Research Expansion :
Growing demand from South Korean pharmaceutical and biotech companies for more predictive preclinical models is driving increased utilization of patient-derived xenografts in drug development pipelines.
South Korea Patient Derived Xenografts/PDX Models Market Dynamics
- The nation's commitment to biotechnology innovation, coupled with increasing collaborations between academic institutions and pharmaceutical companies, is creating favorable conditions for market expansion.
- Government initiatives supporting personalized medicine development are expected to drive sustained demand for PDX models through 2030. The market will benefit from South Korea's skilled workforce in life sciences, advanced laboratory infrastructure, and growing number of clinical trials utilizing PDX-derived insights.
- As international pharmaceutical companies increasingly establish research partnerships in South Korea, the adoption of PDX models for preclinical drug efficacy and safety testing will accelerate, supporting the projected 9.8% CAGR through 2030..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- South Korea's PDX models market is valued at $4.0 million in 2025 and is forecast to reach $6.4 million by 2030, representing a 9.8% compound annual growth rate.
- South Korea's advanced biotechnology infrastructure and government support for precision medicine are key drivers accelerating PDX adoption among pharmaceutical and research institutions.
- South Korea's CROs and academic medical centers are increasingly utilizing PDX models to improve oncology drug development efficiency and reduce clinical trial failure rates.
- South Korea's regulatory framework and investment in translational research position the country for sustained market growth through 2030 in personalized cancer therapeutics.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
South Korea Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
Target Audience
- Pharmaceutical Companies : South Korean and international pharma firms need market data to assess PDX model adoption rates, identify partnership opportunities, and plan preclinical research investments in the region.
- Biotech Research Firms : Biotech companies developing PDX technologies require South Korea-specific market intelligence to evaluate expansion opportunities and understand local demand for advanced preclinical models.
- Contract Research Organizations (CROs) : CROs operating in South Korea need detailed market insights to benchmark services, identify growth opportunities, and develop targeted offerings for local pharmaceutical and biotech clients.
- Academic & Research Institutions : South Korean universities and research centers require market data to secure funding, establish industry partnerships, and align PDX research programs with commercial opportunities.
- Healthcare Investors & Venture Capital : Investment firms targeting South Korea's biotech sector need comprehensive market analysis to identify promising PDX-related companies and assess growth potential in personalized medicine.
Key Companies in the South Korea Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Market-Specific Growth Projections : Access detailed South Korea-specific forecasts showing 9.8% CAGR through 2030, enabling accurate business planning and investment decisions tailored to this emerging market.
- Competitive Landscape Intelligence : Understand the competitive dynamics unique to South Korea's PDX market, including key players, partnerships, and market consolidation trends specific to the region.
- Regulatory & Infrastructure Insights : Gain comprehensive knowledge of South Korea's regulatory environment, biotech infrastructure capabilities, and government support mechanisms driving PDX model adoption.
- Strategic Partnership Opportunities : Identify collaboration opportunities with South Korean research institutions, pharmaceutical companies, and biotech firms actively investing in PDX model development.
- Market Entry & Expansion Strategy : Develop informed market entry strategies for South Korea with localized insights on customer segments, pricing dynamics, and growth drivers specific to the region.
Frequently asked questions
What is the current market size of PDX models in South Korea?
South Korea's Patient Derived Xenografts market was valued at $4.0 million in 2025 and is expected to grow to $6.4 million by 2030.
What is the projected growth rate for South Korea's PDX models market?
South Korea's PDX models market is projected to grow at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2030.
Which sectors are driving PDX adoption in South Korea?
South Korea's pharmaceutical companies, contract research organizations, and academic medical centers are the primary drivers of PDX model adoption for oncology research and drug development.
Why is South Korea a growing market for PDX models?
South Korea's advanced biotechnology infrastructure, government support for precision medicine, and strong investment in translational cancer research are creating favorable conditions for PDX market expansion.
What applications are most common for PDX models in South Korea?
South Korea's primary applications for PDX models include preclinical oncology research, drug efficacy testing, biomarker discovery, and personalized medicine development for cancer therapeutics.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report